Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
Conditions
Interventions
Macitentan
Placebo
Locations
32
United States
Kentuckiana Pulmonary Associates
Louisville, Kentucky, United States
Boston University School of Medicine
Boston, Massachusetts, United States
University of Michigan Internal Medicine Cardiology, Pulmonary Hypertension Program
Ann Arbor, Michigan, United States
Washington University School of Medicine - Center for Advanced Med
St Louis, Missouri, United States
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States
Houston Methodist Hospital - Heart Failure/Pulm Hypertension
Houston, Texas, United States
Start Date
July 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
May 15, 2019
NCT05746039
NCT07073820
NCT03854071
NCT07477197
NCT06899815
NCT07120789
Lead Sponsor
Actelion
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions